Literature DB >> 24780468

The peptidic middle molecules: is molecular weight doing the trick?

Michal Chmielewski1, Gerald Cohen2, Andrzej Wiecek3, Juan Jesús Carrero4.   

Abstract

Chronic kidney disease (CKD) is characterized by a gradual endogenous intoxication caused by the progressive accumulation of bioactive compounds that in normal conditions would be excreted and/or metabolized by the kidney. Uremic toxicity now is understood as one of the potential causes for the excess of cardiovascular disease and mortality observed in CKD. An important family of uremic toxins is that of the peptidic middle molecules, with a molecular weight ranging between 500 and 60,000 Da, which makes them, as a consequence, difficult to remove in the process of dialysis unless the dialyzer pore size is large enough. This review provides an overview of the main and best-characterized peptidic middle molecules and their role as potential culprits of the cardiometabolic complications inherent to CKD patients.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Middle molecules; chronic kidney disease; uremic toxicity

Mesh:

Substances:

Year:  2014        PMID: 24780468     DOI: 10.1016/j.semnephrol.2014.02.005

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  7 in total

1.  Expanded hemodialysis as effective alternative to on-line hemodiafiltration: A randomized mid-term clinical trial.

Authors:  Fernando Hadad-Arrascue; Lars-Göran Nilsson; Angela S Rivera; Angelito A Bernardo; Juan B Cabezuelo Romero
Journal:  Ther Apher Dial       Date:  2021-06-29       Impact factor: 2.195

2.  Gut microbiome in hemodialysis patients treated with calcium acetate or treated with sucroferric oxyhydroxide: a pilot study.

Authors:  Ana Merino-Ribas; Ricardo Araujo; Ioana Bancu; Fredzzia Graterol; Andrea Vergara; Marc Noguera-Julian; Roger Paredes; Jordi Bonal; Benedita Sampaio-Maia
Journal:  Int Urol Nephrol       Date:  2021-12-19       Impact factor: 2.266

3.  Effect of therapeutic plasma exchange on plasma levels and total removal of adipokines and inflammatory markers.

Authors:  Julius J Schmidt; Janine Jahn; Jan T Kielstein; Heike Kielstein; Paulina Golla; Carsten Hafer
Journal:  BMC Obes       Date:  2015-09-30

4.  Clinical Assessment of Dialysis Recovery Time and Symptom Burden: Impact of Switching Hemodialysis Therapy Mode.

Authors:  Stephanie Bolton; Rachel Gair; Lars-Göran Nilsson; Michael Matthews; Louanne Stewart; Natasha McCullagh
Journal:  Patient Relat Outcome Meas       Date:  2021-11-04

Review 5.  Uremic Toxins and Blood Purification: A Review of Current Evidence and Future Perspectives.

Authors:  Stefania Magnani; Mauro Atti
Journal:  Toxins (Basel)       Date:  2021-03-30       Impact factor: 4.546

Review 6.  Chronic Kidney Disease-Associated Itch (CKD-aI) in Children-A Narrative Review.

Authors:  Radomir Reszke; Katarzyna Kiliś-Pstrusińska; Jacek C Szepietowski
Journal:  Toxins (Basel)       Date:  2021-06-29       Impact factor: 4.546

Review 7.  Uremic Toxins and Protein-Bound Therapeutics in AKI and CKD: Up-to-Date Evidence.

Authors:  Jia-Huang Chen; Chih-Kang Chiang
Journal:  Toxins (Basel)       Date:  2021-12-23       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.